Paper39614036
Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions.
Vikal A and 6 others. Drug Deliv Transl Res, 2025. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions. Papers, record 39614036. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39614036
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Proteolysis | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| Animals | |
| Clinical Trials as Topic | |
| Proteolysis Targeting Chimera |
Source PubMed
References174
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35410300 | Proteolysis-targeting chimeras (PROTACs) in cancer therapy. | Mol Cancer | 2022 | https://conductscience.org/library/papers/35410300 | PubMed |
| 2 | 32297626 | A caged E3 ligase ligand for PROTAC-mediated protein degradation with light. | Chem Commun (Camb) | 2020 | https://conductscience.org/library/papers/32297626 | PubMed |
| 3 | 31902710 | Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα). | Bioorg Med Chem Lett | 2020 | https://conductscience.org/library/papers/31902710 | PubMed |
| 4 | 33275901 | Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. | Cell | 2020 | https://conductscience.org/library/papers/33275901 | PubMed |
| 5 | 31047748 | Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges. | Bioorg Med Chem Lett | 2019 | https://conductscience.org/library/papers/31047748 | PubMed |
| 6 | 30012605 | Delineating the role of cooperativity in the design of potent PROTACs for BTK. | Proc Natl Acad Sci U S A | 2018 | https://conductscience.org/library/papers/30012605 | PubMed |
| 7 | 35464214 | Rigidity and Flexibility in Rotaxanes and Their Relatives; On Being Stubborn and Easy-Going. | Front Chem | 2022 | https://conductscience.org/library/papers/35464214 | PubMed |
| 8 | 14749129 | Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. | Cancer Cell | 2004 | https://conductscience.org/library/papers/14749129 | PubMed |
| 9 | 33143537 | E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones. | SLAS Discov | 2021 | https://conductscience.org/library/papers/33143537 | PubMed |
| 10 | 35755293 | NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion. | Acta Pharm Sin B | 2022 | https://conductscience.org/library/papers/35755293 | PubMed |
| 11 | 31097984 | Treatment of Alzheimer's by PROTAC-Tau Protein Degradation. | ACS Med Chem Lett | 2019 | https://conductscience.org/library/papers/31097984 | PubMed |
| 12 | 31660436 | Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs. | ACS Cent Sci | 2019 | https://conductscience.org/library/papers/31660436 | PubMed |
| 13 | 23614556 | Reversible photocontrol of biological systems by the incorporation of molecular photoswitches. | Chem Rev | 2013 | https://conductscience.org/library/papers/23614556 | PubMed |
| 14 | 8902388 | Oncogenic proteins as tumor antigens. | Curr Opin Immunol | 1996 | https://conductscience.org/library/papers/8902388 | PubMed |
| 15 | 35066101 | Wnt/β-catenin signaling in colorectal cancer: Is therapeutic targeting even possible? | Biochimie | 2022 | https://conductscience.org/library/papers/35066101 | PubMed |
| 16 | 34203106 | Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34203106 | PubMed |
| 17 | 26564077 | Von Hippel-Lindau disease. | Handb Clin Neurol | 2015 | https://conductscience.org/library/papers/26564077 | PubMed |
| 18 | 20043028 | Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. | Nat Rev Drug Discov | 2010 | https://conductscience.org/library/papers/20043028 | PubMed |
| 19 | 36733714 | E3 ligase ligand optimization of Clinical PROTACs. | Front Chem | 2023 | https://conductscience.org/library/papers/36733714 | PubMed |
| 20 | 30742854 | Light-triggered release of photocaged therapeutics - Where are we now? | J Control Release | 2019 | https://conductscience.org/library/papers/30742854 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42415161 | Fluorinated Aminopiperidones as Non-Glutarimide Thalidomide Analogs: Stereodivergent Synthesis and Validation. | ChemMedChem | 2026 | https://conductscience.org/library/papers/42415161 | PubMed |
| 42244865 | Research progress and future perspectives in proteolysis-targeting chimeras. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42244865 | PubMed |
| 42187721 | Disrupting the Undruggable: Emerging Modalities for Targeting Protein-Protein Interactions in Oncology. | Biology (Basel) | 2026 | https://conductscience.org/library/papers/42187721 | PubMed |
| 42050258 | The degradation revolution: harnessing targeted protein degradation for the treatment of human diseases. | Cell Mol Life Sci | 2026 | https://conductscience.org/library/papers/42050258 | PubMed |
| 41821623 | Protacs in oral cancer: degrading oncogenic drivers for next-generation therapy. | Front Oral Health | 2026 | https://conductscience.org/library/papers/41821623 | PubMed |
| 41799503 | Research on the Mechanism of "Cold Tumor" Formation and Immunotherapy for Its Transformation into "Hot Tumor". | Oncol Res | 2026 | https://conductscience.org/library/papers/41799503 | PubMed |
| 41750393 | Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms. | Biomolecules | 2026 | https://conductscience.org/library/papers/41750393 | PubMed |
| 41362117 | Next-Generation Proteolysis-Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation. | Drug Dev Res | 2025 | https://conductscience.org/library/papers/41362117 | PubMed |
| 41174249 | Concurrence of FGFR1 mutations modulates oncogenesis in glioneuronal tumors. | EMBO J | 2025 | https://conductscience.org/library/papers/41174249 | PubMed |
| 40874151 | Breaking the oncogenic alliance: advances in disrupting the MTDH-SND1 complex for cancer therapy. | RSC Adv | 2025 | https://conductscience.org/library/papers/40874151 | PubMed |
| 40871058 | Recent Advances in Nanomedicine: Cutting-Edge Research on Nano-PROTAC Delivery Systems for Cancer Therapy. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40871058 | PubMed |
| 40839238 | Tackling tumor hypoxia: advances in breaking the oncogenic HIF-1α-p300/CBP alliance. | Invest New Drugs | 2025 | https://conductscience.org/library/papers/40839238 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39614036
GET https://conductscience.org/api/papers/v1/39614036/references?page=2